Johnson & Johnson’s ICOTYDE®: Breakthrough Data for Plaque Psoriasis Treatment Demonstrates Long-Term Efficacy#USA#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
Johnson & Johnson’s ICOTYDE®: Breakthrough Data for Plaque Psoriasis Treatment Demonstrates Long-Term Efficacy
Johnson & Johnson announces significant two-year results for ICOTYDE® in treating difficult plaque psoriasis, confirming its effectiveness and durability in patients.
third-news.com
October 2, 2026 at 10:14 AM
Johnson & Johnson’s ICOTYDE®: Breakthrough Data for Plaque Psoriasis Treatment Demonstrates Long-Term Efficacy#USA#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
Johnson & Johnson Unveils Promising Long-Term Results for IMAAVY® in Generalized Myasthenia Gravis Patients#USA#Johnson_&_Johnson#Spring_House#Myasthenia_Gravis#IMAAVY
Johnson & Johnson Unveils Promising Long-Term Results for IMAAVY® in Generalized Myasthenia Gravis Patients
New findings from Johnson & Johnson indicate that IMAAVY® effectively sustains disease control and enhances daily functionality in patients with generalized myasthenia gravis.
third-news.com
September 29, 2026 at 12:15 PM
Johnson & Johnson Unveils Promising Long-Term Results for IMAAVY® in Generalized Myasthenia Gravis Patients#USA#Johnson_&_Johnson#Spring_House#Myasthenia_Gravis#IMAAVY
TREMFYA® Breakthrough: First IL-23 Inhibitor to Alleviate Spinal Pain in Psoriatic Arthritis#USA#Spring_House#TREMFYA#guselkumab#Psoriatic_Arthritis
TREMFYA® Breakthrough: First IL-23 Inhibitor to Alleviate Spinal Pain in Psoriatic Arthritis
Johnson & Johnson has revealed that TREMFYA® (guselkumab) is the first IL-23 inhibitor to show significant improvements in spinal symptoms of axial psoriatic arthritis, as evidenced in the STAR study.
third-news.com
September 25, 2026 at 11:38 AM
TREMFYA® Breakthrough: First IL-23 Inhibitor to Alleviate Spinal Pain in Psoriatic Arthritis#USA#Spring_House#TREMFYA#guselkumab#Psoriatic_Arthritis
FDA's Historic Approval of IMAAVY®: A Breakthrough in Treating wAIHA#USA#Johnson_&_Johnson#Spring_House#IMAAVY#warm_autoimmune_hemolytic_anemia
FDA's Historic Approval of IMAAVY®: A Breakthrough in Treating wAIHA
IMAAVY® is now the first approved treatment for warm autoimmune hemolytic anemia (wAIHA), a significant advancement for patients facing this rare disease.
third-news.com
August 24, 2026 at 11:21 PM
FDA's Historic Approval of IMAAVY®: A Breakthrough in Treating wAIHA#USA#Johnson_&_Johnson#Spring_House#IMAAVY#warm_autoimmune_hemolytic_anemia
FDA Accelerates Review of IMAAVY®, a Promising New Treatment for wAIHA#USA#Johnson_&_Johnson#Spring_House#IMAAVY#warm_autoimmune_hemolytic_anemia
FDA Accelerates Review of IMAAVY®, a Promising New Treatment for wAIHA
The FDA has granted Priority Review for IMAAVY®, potentially the first approved treatment for warm autoimmune hemolytic anemia, highlighting its significant impact on patient safety and effectiveness.
third-news.com
April 27, 2026 at 12:15 PM
FDA Accelerates Review of IMAAVY®, a Promising New Treatment for wAIHA#USA#Johnson_&_Johnson#Spring_House#IMAAVY#warm_autoimmune_hemolytic_anemia
Long-Term Efficacy and Safety of ICOTYDE™ in Plaque Psoriasis Patients Revealed#United_States#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
Long-Term Efficacy and Safety of ICOTYDE™ in Plaque Psoriasis Patients Revealed
Johnson & Johnson reported promising year-long results for ICOTYDE™, a once-daily oral treatment for plaque psoriasis, confirming its effectiveness and safety.
third-news.com
March 28, 2026 at 2:14 PM
Long-Term Efficacy and Safety of ICOTYDE™ in Plaque Psoriasis Patients Revealed#United_States#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
A Colorful Spring Weekend: 'Spring House' by My Little Box Draws Over 750 Fans#Japan#Spring_House#Tokyo#Shu_Uemura#My_Little_Box
A Colorful Spring Weekend: 'Spring House' by My Little Box Draws Over 750 Fans
Over 750 fans gathered in Daikanyama for the 'Spring House' event by My Little Box, celebrating spring with exclusive beauty collaborations and experiences.
third-news.com
March 25, 2026 at 2:44 AM
A Colorful Spring Weekend: 'Spring House' by My Little Box Draws Over 750 Fans#Japan#Spring_House#Tokyo#Shu_Uemura#My_Little_Box
ICOTYDE™: A Breakthrough Oral Treatment Approved for Plaque Psoriasis#United_States#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
ICOTYDE™: A Breakthrough Oral Treatment Approved for Plaque Psoriasis
Johnson & Johnson's ICOTYDE™ has received FDA approval as a novel oral treatment for moderate-to-severe plaque psoriasis, a significant advancement for patient care.
third-news.com
March 18, 2026 at 11:57 AM
ICOTYDE™: A Breakthrough Oral Treatment Approved for Plaque Psoriasis#United_States#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment#United_States#Johnson_&_Johnson#Spring_House#nipocalimab#Systemic_Lupus
Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment
Nipocalimab, a novel treatment developed by Johnson & Johnson, has received Fast Track designation from the FDA for lupus therapy, addressing critical patient needs.
third-news.com
March 3, 2026 at 1:38 PM
Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment#United_States#Johnson_&_Johnson#Spring_House#nipocalimab#Systemic_Lupus
Johnson & Johnson Pursues FDA Approval for Groundbreaking wAIHA Treatment with IMAAVY®#United_States#Johnson_&_Johnson#Spring_House#IMAAVY#wAIHA
Johnson & Johnson Pursues FDA Approval for Groundbreaking wAIHA Treatment with IMAAVY®
Johnson & Johnson has submitted a new drug application to the FDA seeking to make IMAAVY® the first-ever approved treatment for warm autoimmune hemolytic anemia (wAIHA), a serious disease.
third-news.com
February 24, 2026 at 9:19 PM
Johnson & Johnson Pursues FDA Approval for Groundbreaking wAIHA Treatment with IMAAVY®#United_States#Johnson_&_Johnson#Spring_House#IMAAVY#wAIHA
Third Arc Bio Secures $52 Million to Enhance Cancer and Immune Therapies#United_States#Spring_House#oncology#Immunology#Third_Arc_Bio
Third Arc Bio Secures $52 Million to Enhance Cancer and Immune Therapies
Third Arc Bio has successfully raised $52 million in a Series A funding extension, aiming to boost its oncology and immunology portfolio with groundbreaking therapies.
third-news.com
February 4, 2026 at 12:23 PM
Third Arc Bio Secures $52 Million to Enhance Cancer and Immune Therapies#United_States#Spring_House#oncology#Immunology#Third_Arc_Bio
Johnson & Johnson Reports Breakthrough Results in SLE Treatment with Nipocalimab#USA#Johnson_&_Johnson#Spring_House#nipocalimab#Systemic_Lupus_Erythematosus
Johnson & Johnson Reports Breakthrough Results in SLE Treatment with Nipocalimab
Johnson & Johnson has announced promising Phase 2 results for nipocalimab, the first investigational FcRn blocker aimed at treating systemic lupus erythematosus.
third-news.com
January 6, 2026 at 1:15 PM
Johnson & Johnson Reports Breakthrough Results in SLE Treatment with Nipocalimab#USA#Johnson_&_Johnson#Spring_House#nipocalimab#Systemic_Lupus_Erythematosus
Johnson & Johnson Initiates First Head-to-Head Study for gMG Treatment Comparison at AANEM#USA#Johnson_&_Johnson#Spring_House#IMAAVY™#gMG_Treatment
Johnson & Johnson Initiates First Head-to-Head Study for gMG Treatment Comparison at AANEM
Johnson & Johnson has launched a pivotal study, the EPIC trial, comparing its IMAAVY™ with efgartigimod to assess treatment for generalized myasthenia gravis.
third-news.com
October 29, 2025 at 12:10 PM
Johnson & Johnson Initiates First Head-to-Head Study for gMG Treatment Comparison at AANEM#USA#Johnson_&_Johnson#Spring_House#IMAAVY™#gMG_Treatment
New Study Reveals Unmet Needs in Psoriasis Care, Highlighting Preference for Oral Treatments#USA#Johnson_&_Johnson#Spring_House#Psoriasis#Oral_Treatments
New Study Reveals Unmet Needs in Psoriasis Care, Highlighting Preference for Oral Treatments
A recent study highlights significant unmet needs in psoriasis treatments, with patients showing a strong preference for effective oral medications over injectables.
third-news.com
October 27, 2025 at 12:24 PM
New Study Reveals Unmet Needs in Psoriasis Care, Highlighting Preference for Oral Treatments#USA#Johnson_&_Johnson#Spring_House#Psoriasis#Oral_Treatments
Nipocalimab's Promising Impact on Sjögren's Disease: Insights from Recent Study#United_States#Johnson_&_Johnson#Spring_House#nipocalimab#Sjögren's_Disease
Nipocalimab's Promising Impact on Sjögren's Disease: Insights from Recent Study
Recent findings reveal that nipocalimab significantly reduced disease activity in patients with Sjögren's disease, showcasing its potential as a transformative therapy.
third-news.com
October 24, 2025 at 10:34 PM
Nipocalimab's Promising Impact on Sjögren's Disease: Insights from Recent Study#United_States#Johnson_&_Johnson#Spring_House#nipocalimab#Sjögren's_Disease
Long-term Results for Icotrokinra Show Promise in Clearing Psoriasis#USA#Johnson_&_Johnson#Spring_House#Psoriasis#Icotrokinra
Long-term Results for Icotrokinra Show Promise in Clearing Psoriasis
New long-term results from the Phase 3 ICONIC-TOTAL study reveal that Icotrokinra offers significant skin clearance and safety for psoriasis patients.
third-news.com
October 24, 2025 at 12:10 PM
Long-term Results for Icotrokinra Show Promise in Clearing Psoriasis#USA#Johnson_&_Johnson#Spring_House#Psoriasis#Icotrokinra
Icotrokinra: A Promising New Treatment for Ulcerative Colitis#United_States#Ulcerative_Colitis#Johnson_&_Johnson#Spring_House#Icotrokinra
Icotrokinra: A Promising New Treatment for Ulcerative Colitis
Icotrokinra demonstrates significant therapeutic benefits and safety for ulcerative colitis patients, as seen in recent clinical trials. The once-daily pill showed impressive clinical response rates and remission improvements.
third-news.com
October 7, 2025 at 12:18 PM
Icotrokinra: A Promising New Treatment for Ulcerative Colitis#United_States#Ulcerative_Colitis#Johnson_&_Johnson#Spring_House#Icotrokinra
TREMFYA®: A Breakthrough in Ulcerative Colitis Treatment with Sustained Results#USA#Ulcerative_Colitis#TREMFYA®#Spring_House#guselkumab
TREMFYA®: A Breakthrough in Ulcerative Colitis Treatment with Sustained Results
TREMFYA® (guselkumab) emerges as the first IL-23 inhibitor with a fully subcutaneous regimen, showing remarkable results in ulcerative colitis treatment over 48 weeks.
third-news.com
October 7, 2025 at 12:16 PM
TREMFYA®: A Breakthrough in Ulcerative Colitis Treatment with Sustained Results#USA#Ulcerative_Colitis#TREMFYA®#Spring_House#guselkumab
Icotrokinra Outshines Deucravacitinib in Head-to-Head Phase 3 Trials for Plaque Psoriasis Treatment#USA#Spring_House#Psoriasis#Icotrokinra#Deucravacitinib
Icotrokinra Outshines Deucravacitinib in Head-to-Head Phase 3 Trials for Plaque Psoriasis Treatment
Recent Phase 3 trials reveal Icotrokinra's effectiveness over Deucravacitinib for treating moderate-to-severe plaque psoriasis, promising a new oral peptide treatment option.
third-news.com
September 17, 2025 at 12:20 PM
Icotrokinra Outshines Deucravacitinib in Head-to-Head Phase 3 Trials for Plaque Psoriasis Treatment#USA#Spring_House#Psoriasis#Icotrokinra#Deucravacitinib
Johnson & Johnson Files for ICOTROKINRA FDA Approval, Pioneering Psoriasis Treatment for All Ages#USA#Johnson_&_Johnson#Spring_House#Psoriasis#Icotrokinra
Johnson & Johnson Files for ICOTROKINRA FDA Approval, Pioneering Psoriasis Treatment for All Ages
Johnson & Johnson aims to change psoriasis treatment with icotrokinra, an oral peptide that targets IL-23 receptors, offering hope for patients aged 12 and older.
third-news.com
July 21, 2025 at 12:18 PM
Johnson & Johnson Files for ICOTROKINRA FDA Approval, Pioneering Psoriasis Treatment for All Ages#USA#Johnson_&_Johnson#Spring_House#Psoriasis#Icotrokinra
IMAAVY™: A New Hope for Generalized Myasthenia Gravis Patients with Enhanced Disease Control#USA#Spring_House#IMAAVY™_Generalized_Myasthenia_Gravis
IMAAVY™: A New Hope for Generalized Myasthenia Gravis Patients with Enhanced Disease Control
Recent data highlights IMAAVY™'s superior disease control over existing treatments for generalized myasthenia gravis, offering hope to patients with this chronic condition.
third-news.com
June 23, 2025 at 11:39 AM
IMAAVY™: A New Hope for Generalized Myasthenia Gravis Patients with Enhanced Disease Control#USA#Spring_House#IMAAVY™_Generalized_Myasthenia_Gravis
Icotrokinra Shows Promising Results in Treating Scalp and Genital Psoriasis#USA#Johnson_&_Johnson#Spring_House#Psoriasis#Icotrokinra
Icotrokinra Shows Promising Results in Treating Scalp and Genital Psoriasis
New findings from a Phase 3 study reveal that icotrokinra significantly improves skin conditions for patients suffering from psoriasis in hard-to-treat areas.
third-news.com
May 9, 2025 at 12:52 PM
Icotrokinra Shows Promising Results in Treating Scalp and Genital Psoriasis#USA#Johnson_&_Johnson#Spring_House#Psoriasis#Icotrokinra
FDA Approves IMAAVY™: A New Milestone for Myasthenia Gravis Treatment#United_States#Johnson_&_Johnson#Spring_House#Myasthenia_Gravis#IMAAVY
FDA Approves IMAAVY™: A New Milestone for Myasthenia Gravis Treatment
Johnson & Johnson's IMAAVY™ has received FDA approval, providing a significant advancement in treating generalized myasthenia gravis with lasting effects for patients.
third-news.com
April 30, 2025 at 12:57 PM
FDA Approves IMAAVY™: A New Milestone for Myasthenia Gravis Treatment#United_States#Johnson_&_Johnson#Spring_House#Myasthenia_Gravis#IMAAVY